Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
Treatment and Mana...
...to Treat...
...Endocrine Society (ES) recommends treating post...
...isphosphonates...
...1: In postmenopausal women at high risk of frac...
...2: In postmenopausal women with osteoporosis wh...
Denosumab
...tmenopausal women with osteoporosis who are at...
...ostmenopausal women with osteoporosis who...
...stmenopausal women with osteoporosis taki...
...riparatide and Abaloparatide...
...n postmenopausal women with osteopor...
...nopausal women with osteoporosis who have co...
...osozumab...
A.1: In postmenopausal women with osteopo...
...opausal women with osteoporosis who have...
...elective Estrogen Receptor Modulator...
...postmenopausal women with osteoporos...
...ausal Hormone Therapy and Tibo...
6.1: In postmenopausal women at high...
...postmenopausal women with osteoporosi...
...lcitonin
...postmenopausal women at high risk of fracture wit...
...cium and Vitami...
...ostmenopausal women with low BMD and at high...
....2: In postmenopausal women at high risk o...
Monitoring
9.1: In postmenopausal women with a low...
Figure 1. Algorithm for the Managem...